Novonesis Signs Deal to Manufacture TurtleTree’s Precision-Fermented Lactoferrin

Novonesis has signed a deal with TurtleTree to manufacture and commercialize the precision-fermented lactoferrin ingredient, LF+®. Novonesis will exclusively handle scaling and manufacturing for the early life nutrition market, with selected rights for dietary supplements. This partnership aims to make lactoferrin more accessible and cost-effective through precision fermentation, addressing supply limitations and driving down costs.

TurtleTree's fermentation technology will be paired with Novonesis's manufacturing and commercial infrastructure to ensure cost-effective and consistent supply at scale. The companies believe this partnership will enable customers to deliver proven health benefits to consumers more efficiently. With a focus on unlocking the unique benefits of lactoferrin using precision fermentation, the collaboration aims to provide modern health brands with the consistency, cost structure, and supply reliability needed to meet consumer demands.